Globenewswire
Genmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified Phase 3 EPCORE DLBCL-1 epcoritamab results. In the U.S., overall survival (OS) was the sole primary endpoint and was not met versus investigator’s choice chemoimmunotherapy (R-GemOx or BR) in relapsed/refractory DLBCL ineligible for transplant. Additional results will be submitted for publication.
How this was made
The 30-second read
Why it matters
This PR clarifies that in the US, overall survival (OS) was the sole primary endpoint and was not met, which is a direct negative efficacy signal for epcoritamab in this Phase 3 setting.
Market read
Traders may reprice epcoritamab’s Phase 3 probability-weighted value in R/R DLBCL based on the explicit US OS primary endpoint miss.
What to watch
The companies state additional results will be submitted for publication and highlight ongoing EPCORE programs (DLBCL-2 and DLBCL-4), which could offset this specific endpoint disappointment if efficacy signals emerge elsewhere.
Background
Genmab and AbbVie previously announced EPCORE DLBCL-1 topline results (Jan 16, 2026) and later presented additional data at EHA 2026 (Jun 12, 2026).
Ticker impact
Genmab clarifies EPCORE DLBCL-1 US primary endpoint was OS and it was not met, despite prior topline results.
Near-term sentiment likely negative for GMAB tied to epcoritamab efficacy expectations, with focus shifting to other EPCORE programs.
The release explicitly states the sole US primary endpoint (OS) was not met, which directly affects perceived clinical value of epcoritamab in this setting.
AbbVie clarifies EPCORE DLBCL-1 US primary endpoint was OS and was not met for epcoritamab in R/R DLBCL.
Potential downside pressure as investors reassess probability of further label expansion or durability in this trial.
The statement is unambiguous: OS was the sole US primary endpoint and did not demonstrate statistically significant improvement.
Market effects
Reinforces that T-cell engaging bispecifics can face OS endpoint challenges in Phase 3, potentially raising scrutiny on trial design and endpoint selection.
Primarily US trial endpoint clarification may influence US-focused oncology sentiment for lymphoma therapies.
May affect global investor perception of epcoritamab’s Phase 3 trajectory while other EPCORE readouts are awaited in 2026.
Counterpoint
Because the release frames OS as the sole US primary endpoint and notes other regional endpoints differ, investors may wait for non-US results or secondary outcomes before fully downgrading the program.
Key entities
- clinical_trialEPCORE DLBCL-1
Phase 3 randomized trial of epcoritamab vs investigator’s choice chemoimmunotherapy in R/R DLBCL ineligible for autologous stem cell transplant.
- drugepcoritamab (DuoBody-CD3xCD20)
T-cell engaging bispecific antibody co-developed by Genmab and AbbVie; approved under FDA accelerated approval in certain R/R DLBCL indications.
- companyGenmab
Co-developer of epcoritamab; clarifies US primary endpoint OS was not met in EPCORE DLBCL-1.
- companyAbbVie
Co-developer and responsible for further global commercialization; clarifies US OS primary endpoint was not met.
